Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Acute Myeloid Leukemia|Myelodysplastic Syndrome
DRUG: BMS-986497|DRUG: Azacitidine|DRUG: Venetoclax
Incidence of dose-limiting toxicities (DLTs), Up to 21 days|Incidence of treatment-emergent adverse events (TEAEs), Up to 2 years|Determine the Recommended Phase 2 Dose (RP2D) of BMS-986497 as Monotherapy, Up to 2 years|RP2D of BMS-986497 as Combination Therapy, The combination therapy included BMS-986497 and Azacitidine, Up to 2 years|RP2D of BMS-986497 as Triple Combination Therapy, The triple combination therapy included BMS-986497, Azacitidine and Venetoclax., Up to 2 years
Maximum concentration (Cmax), Up to 2 years|Time to reach Cmax (Tmax), Up to 2 years|Area under the curve from time 0 to last quantifiable concentration (AUC0-last), Up to 2 years|Overall response rate (ORR), Up to 4 years|Duration of response (DoR), Up to 4 years|Best overall response (BOR), Up to 4 years|Complete remission (CR), Up to 4 years|Complete remission with incomplete hematologic recovery (Cri), Up to 4 years|Complete remission with partial hematologic recovery (CRh) rate, Up to 4 years|Event-free survival (EFS), Up to 4 years|Transition rate to allogeneic hematopoietic stem cell transplantation (HSCT), Up to 4 years|Incidence of Anti-drug antibody (ADA) against BMS-986497, Up to 2 years
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).